Accessibility Menu
Basilea Pharmaceutica Ag logo

Basilea Pharmaceutica Ag(OTC) BPMUF

Market Cap$960.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)+53%
5 Year+68%
1 Year+14%
1 Month+28%
$77.40
+0.00%
+0.00Today
Basilea Pharmaceutica Ag last closing stock price
MetricPriceDate
Last closeUSD 77.402026-08-19
Basilea Pharmaceutica Ag stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+18.17%USD 65.502026-08-06
1 month+28.41%USD 60.282026-06-10
3 month+18.89%USD 65.102026-05-18
Year to date+22.37%USD 63.252025-12-04
1 year+14.24%USD 67.752025-07-30
3 year+54.8%USD 50.002023-06-08
5 year+68.26%USD 46.002021-07-16
Since inception+53.27%USD 50.502004-08-24

Basilea Pharmaceutica Ag Financials at a Glance

Market Cap

$960.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CHF 483.04M

Net Income (TTM)

CHF 124.86M

EPS (TTM)

$4.92

P/E Ratio

14.45

Dividend

$0.00

Beta (Volatility)

-0.00 (Low)

Price

$77.40

Volume

100

Open

$77.40

Previous Close

$77.40

Daily Range

$77.40 - $77.40

52-Week Range

$59.29 - $77.40

Estimated Earnings Date

Feb 16, 2027

BPMUF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Basilea Pharmaceutica Ag

Basilea Pharmaceutica AG is a biopharmaceutical company focused on developing innovative therapies for oncology and infectious diseases. The company generates revenue from its products, including Cresemba and Zevtera, which address significant medical needs in challenging therapeutic areas.

Products and Services
  • Cresemba: An antifungal drug for invasive aspergillosis and mucormycosis
  • Zevtera: An antibiotic for community-acquired and hospital-acquired pneumonia
  • Pipeline: Includes Derazantinib for bile duct cancer and Lisavanbulin as a tumor checkpoint controller
Growth Outlook
  • Cresemba is in Phase III trials in Japan, expanding market potential
  • Zevtera is advancing through Phase III studies for additional indications
  • Strong pipeline with multiple candidates in various stages of clinical trials
Financial Highlights
  • Recent quarterly revenue of 128.5 million CHF, showing significant growth
  • Net income of 24.4 million CHF in the latest quarter, indicating profitability
  • Strong cash position with 29.7 million CHF in cash and equivalents
Basilea Pharmaceutica AG is well-positioned in the biotechnology sector, with a focus on unmet medical needs. The company's products, Cresemba and Zevtera, are already generating revenue and have the potential for further growth through ongoing clinical trials. The robust pipeline, including promising candidates like Derazantinib and Lisavanbulin, highlights the company's commitment to innovation. Recent financial performance indicates a positive trajectory, with substantial revenue growth and profitability in the latest quarter. The strong cash position provides a solid foundation for future development and expansion.
AI Generated • Aug 18, 2026

Industry

Biotechnology

Sector

Health Care

Employees

189

CEO

David Veitch

Website

www.basilea.com

Headquarters

Allschwil, BL 4123, CH

BPMUF Financials

Key Financial Metrics (TTM)

Gross Margin

87.67%

Operating Margin

23.90%

Net Income Margin

21.15%

Return on Equity

36.06%

Return on Capital

23.77%

Return on Assets

17.56%

Earnings Yield

6.92%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$960.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

12.40M

Volume

100

Avg. Volume

1.841

Financials (TTM)

Gross Profit

CHF 403.13M

Operating Income

CHF 134.94M

EBITDA

CHF 144.74M

Operating Cash Flow

CHF 137.42M

Capital Expenditure

-CHF 4.35M

Free Cash Flow

CHF 133.07M

Cash & ST Invst.

CHF 174.99M

Total Debt

CHF 82.97M

Basilea Pharmaceutica Ag Performance Analysis

Basilea Pharmaceutica Ag annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CHF 154,717,199-4.5%
20232023-12-31CHF 175,411,66513.4%
20242024-12-31CHF 236,801,04535.0%
20252025-12-31CHF 279,811,98118.2%
Basilea Pharmaceutica Ag sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3173.3%
Q22025-06-30-21.4%
Q42025-12-3123.6%
Q22026-06-30-7.9%
Basilea Pharmaceutica Ag annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CHF 1.06N/A
20232023-12-31CHF 0.96-10.1%
20242024-12-31CHF 6.61590.6%
20252025-12-31CHF 3.78-42.8%
Basilea Pharmaceutica Ag sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31180.0%
Q22025-06-30-70.0%
Q42025-12-3158.7%
Q22026-06-300.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CHF 118.33M

+55.1%

Gross Profit

CHF 102.99M

+319.0%

Gross Margin

87.03%

N/A

Market Cap

$960.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$5.08M

N/A

Employees

189

N/A

Net Income

CHF 27.79M

+34.0%

EBITDA

CHF 34.08M

+235.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CHF 174.99M

+177.9%

Total Debt

CHF 82.97M

-26.2%

Accounts Receivable

CHF 67.79M

+141.4%

Inventory

CHF 25.89M

-17.5%

Long Term Debt

CHF 80.92M

-26.7%

Short Term Debt

CHF 2.05M

-0.6%

Return on Assets

17.56%

N/A

Return on Invested Capital

23.06%

N/A

Free Cash Flow

CHF 18.46M

+5.8%

Operating Cash Flow

CHF 18.87M

+5.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
INRLFValneva SE
$3.29-4.64%
SOLTFNxera Pharma Co., Ltd.
$5.01+0.00%
PTCHFPureTech Health plc
$1.57+0.00%
VBIZFViva Biotech Holdings
$0.17+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.77+0.10%
IBITiShares Bitcoin Trust
$43.68+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$10.41+0.06%
MARAMara Holdings
$11.26+0.01%

Questions About BPMUF

What is the current price of Basilea Pharmaceutica Ag?

Basilea Pharmaceutica Ag is trading at $77.40 per share.

What is the 52-week range for Basilea Pharmaceutica Ag?

Over the past 52 weeks, Basilea Pharmaceutica Ag has traded between $59.29 and $77.40.

How much debt does Basilea Pharmaceutica Ag have?

As of the most recent reporting period, Basilea Pharmaceutica Ag reported total debt of CHF 112.61M.

How much cash does Basilea Pharmaceutica Ag have on hand?

Basilea Pharmaceutica Ag reported CHF 37.41M in cash and cash equivalents in its most recent financial results.

What is Basilea Pharmaceutica Ag’s dividend yield?

Basilea Pharmaceutica Ag does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services